BiomX Inc. HLSQ
0.53
0.00
0.00%
as of 25 Sep
- Market cap
- $1.5M
- P/E
- 0.0×
Follow HLSQ
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (781.27%) | 698.92% | 502.21% | (589.93%) |
+8 more TTM periods Free account |
|
| (137.13%) | (194.99%) | (147.70%) | (76.15%) | ||
ROIC |
(112.08%) | 0.00% | 0.00% | (979.68%) | |
Return on Tangible Assets |
592.65% | (8,000.00%) | 4,502.36% | (493.98%) | |
Average Days of Receivables |
0.00 | — | — | — | |
Free Cash Flow per Share |
(17.55) | (88.68) | (161.14) | (170.62) | |
Free Cash Flow |
(18.10) | (23.09) | (26.28) | (28.19) | |
Capital Expenditures |
0.06 | — | 0.11 | 0.11 | |
Piotroski F-Score |
2.00 | — | — | — | |
| Other line items | |||||
Cash ROIC |
(92.91%) | (8,045.99%) | (722.42%) | (153.82%) | |
Accounts Receivable Turnover |
0.00 | — | — | — | |
Accounts Payable Turnover |
0.58 | 0.00 | 0.00 | 0.00 | |
Inventory Turnover |
0.00 | — | — | — | |
Average Days of Payables |
370.72 | 0.00 | 0.00 | 0.00 | |
Days of Inventory on Hand |
0.00 | — | — | — | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.40 | 0.48 | 0.73 | 0.86 | |
Depreciation/Fixed assets |
26.64 | — | 0.00 | 0.90 | |
Capex/Depreciation |
0.02 | — | 0.04 | 0.04 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(17.60) | (88.68) | (161.80) | (171.27) | |
Capex per Share |
0.05 | 0.00 | 0.66 | 0.64 | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates